BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 25743883)

  • 1. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
    Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
    Chou YS; Gau JP; Yu YB; Pai JT; Hsiao LT; Liu JH; Hong YC; Liu CY; Yang CF; Chen PM; Chiou TJ; Tzeng CH
    Eur J Haematol; 2013 Mar; 90(3):228-36. PubMed ID: 23281576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
    Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
    Am J Hematol; 2010 Feb; 85(2):97-100. PubMed ID: 20052743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
    Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
    Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
    Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
    Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
    Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
    Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
    [No Abstract]   [Full Text] [Related]  

  • 15. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC; Gómez M
    Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
    Landolfi R; Di Gennaro L
    Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
    Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
    Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
    Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
    van Genderen PJ; Leenknegt H; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):385-9. PubMed ID: 9263356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.